1. Israel Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Elbit Medical Technologies Ltd

Elbit Medical Technologies Ltd

EMTC-M.TA
Elbit Medical Technologies LtdIL flagTel Aviv Stock Exchange
22.20
ILA
-1.80
- -
20.14MMarket Cap
Elbit Medical Technologies Ltd
EMTC-M.TA
(Tel Aviv Stock Exchange)

Recent

price

22.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
0.17
-0.05
-0.04
-0.07
-0.08
-0.05
0.12
-0.09
0.99
-0.17
-0.06
-0.2
0.01
0.01
Basic EPS, GAAP
-0.08
- -
- -
- -
- -
- -
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.49
-0.52
-0.59
-0.67
-0.72
-0.6
-0.69
-0.3
-0.59
-0.64
-0.83
-0.82
-0.42
Book Value per Share
- -
0.03
- -
-0.06
-0.14
-0.18
-0.07
-0.16
0.37
0.34
0.28
0.08
0.09
0.4
Tangible Book Value per Share
225
227
231
231
231
231
231
231
124
89
91
91
91
97
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
39
-12
-9
-16
-19
-11
27
-21
123
-16
-5
-18
1
1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-1
- -
- -
- -
- -
2
1
8
3
2
1
1
7
Working Capital
- -
31
32
34
37
42
39
47
32
- -
- -
- -
- -
- -
LT Debt
- -
7
1
-13
-32
-42
-15
-37
46
31
25
7
8
39
Total Equity
- -
- -
- -
- -
- -
- -
-7.79
- -
-1.38
- -
- -
- -
-6.49
-0.65
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-28.05
- -
-213.52
- -
- -
- -
-1.1
-40.87
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
ST Debt
- -
31
31
LT Borrowings
32
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
93
93
93
Market Capitalization
59
46
48

Working Capital

FRC

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
Total Current Assets
10
43
39
Cash, Cash Equivalents & STI
6
4
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
32
32
Payables & Accruals
- -
- -
- -
ST Debt
- -
31
31
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-153.81%
-67.41%
11.46%
Free Cash Flow
5.35%
-0.12%
-8.14%
Net Income, GAAP
-120.13%
-143.21%
-104.65%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.2
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Heyu Biological Technology Corporation (HYBT)
Intersect ENT, Inc. (XENT)
Shanghai Kinetic Medical Co., Ltd (300326.SZ)
Intuitive Surgical, Inc. (0R29.L)
Dignitana AB (publ) (DIGN.ST)
IRadimed Corporation (IRMD)
Business
Elbit Medical Technologies Ltd (TASE: EMTC-M) operates as an investment holding company focused on the research, development, production, and marketing of therapeutic medical systems and life sciences technologies in the United States, Europe, and internationally. The company holds interests in subsidiaries and investments including Insightec Ltd, which develops MRI-guided focused ultrasound systems such as the ExAblate platform for non-invasive treatments targeting oncology, gynecology, neurological disorders, and tumors; Gamida Cell Ltd, which researches and develops stem cell-based therapies derived primarily from umbilical cord blood for bone marrow transplants in patients with leukemia, lymph node cancer, non-malignant blood diseases, and metabolic genetic disorders; and emerging technologies like BeyeOnics surgical visualization platforms and EchoCare remote patient monitoring systems for senior care. Headquartered in Petah Tikva, Israel, at 3 Shimshon Street, the company, founded in 1992, serves healthcare providers, clinicians, and patients in the medical equipment and biotechnology sectors without generating direct revenue as a pre-revenue entity. Recent developments include reporting net income of ILS 3.06 million for the fiscal year alongside an annual general meeting in May 2025, continuation as a maintenance-listed entity following its 2022 shell company designation, and historical strategic moves such as the prior divestment of a significant stake in Insightec for $102 million and Insightec's investment agreement with GE HealthCare reflecting a $106.4 million post-money valuation.